Age-related toxicity in patients with rhabdomyosarcoma: A report from the children's oncology group

Sadaf Altaf, Felicity T Enders, Elizabeth Lyden, Sarah S. Donaldson, David Rodeberg, Carola A.S. Arndt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

On the Fourth Intergroup Rhabdomyosarcoma study, older children experienced excessive neurotoxicity, whereas younger children had increased myelosuppression. The purpose of this study was to determine whether the same pattern of toxicity was seen on the successor study when use of growth factor was required and dosing of chemotherapy was different by performing a retrospective cohort analysis on patients treated on Children's Oncology Group protocol D9803. Toxicity data were analyzed by stratifying children into 4 age groups. The frequency of grade 3/4 neurotoxicity, myelosuppression, infection, and mucositis was predicted for each age group. The cumulative doses of vincristine and cyclophosphamide administered were measured as percent of protocol-prescribed dose. Adolescents (aged 15+) were more likely to experience neurotoxicity compared with younger patients (odds ratio, 3.6; P<0.0001). There was no difference in myelosuppression, infection, or mucositis. The mean percent protocol-prescribed doses administered for vincristine and cyclophosphamide did not differ much by age group. Adolescents experienced more neurotoxicity with vincristine compared with younger patients. No differences in other toxicities were observed between age groups. As adolescents received at least 85% of protocol-prescribed doses of vincristine, it is difficult to attribute the poorer survival in this age group to inadequate protocol-delivered therapy.

Original languageEnglish (US)
Pages (from-to)599-604
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume36
Issue number8
StatePublished - Nov 8 2014

Fingerprint

Rhabdomyosarcoma
Vincristine
Age Groups
Mucositis
Cyclophosphamide
Infection
Intercellular Signaling Peptides and Proteins
Cohort Studies
Odds Ratio
Drug Therapy
Survival

Keywords

  • Age
  • Chemotherapy
  • Mucositis
  • Neurotoxicity
  • Neutropenia
  • Rhabdomyosarcoma
  • Toxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Age-related toxicity in patients with rhabdomyosarcoma : A report from the children's oncology group. / Altaf, Sadaf; Enders, Felicity T; Lyden, Elizabeth; Donaldson, Sarah S.; Rodeberg, David; Arndt, Carola A.S.

In: Journal of Pediatric Hematology/Oncology, Vol. 36, No. 8, 08.11.2014, p. 599-604.

Research output: Contribution to journalArticle

@article{7580c367fda740a6bf195b5d2c204376,
title = "Age-related toxicity in patients with rhabdomyosarcoma: A report from the children's oncology group",
abstract = "On the Fourth Intergroup Rhabdomyosarcoma study, older children experienced excessive neurotoxicity, whereas younger children had increased myelosuppression. The purpose of this study was to determine whether the same pattern of toxicity was seen on the successor study when use of growth factor was required and dosing of chemotherapy was different by performing a retrospective cohort analysis on patients treated on Children's Oncology Group protocol D9803. Toxicity data were analyzed by stratifying children into 4 age groups. The frequency of grade 3/4 neurotoxicity, myelosuppression, infection, and mucositis was predicted for each age group. The cumulative doses of vincristine and cyclophosphamide administered were measured as percent of protocol-prescribed dose. Adolescents (aged 15+) were more likely to experience neurotoxicity compared with younger patients (odds ratio, 3.6; P<0.0001). There was no difference in myelosuppression, infection, or mucositis. The mean percent protocol-prescribed doses administered for vincristine and cyclophosphamide did not differ much by age group. Adolescents experienced more neurotoxicity with vincristine compared with younger patients. No differences in other toxicities were observed between age groups. As adolescents received at least 85{\%} of protocol-prescribed doses of vincristine, it is difficult to attribute the poorer survival in this age group to inadequate protocol-delivered therapy.",
keywords = "Age, Chemotherapy, Mucositis, Neurotoxicity, Neutropenia, Rhabdomyosarcoma, Toxicity",
author = "Sadaf Altaf and Enders, {Felicity T} and Elizabeth Lyden and Donaldson, {Sarah S.} and David Rodeberg and Arndt, {Carola A.S.}",
year = "2014",
month = "11",
day = "8",
language = "English (US)",
volume = "36",
pages = "599--604",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Age-related toxicity in patients with rhabdomyosarcoma

T2 - A report from the children's oncology group

AU - Altaf, Sadaf

AU - Enders, Felicity T

AU - Lyden, Elizabeth

AU - Donaldson, Sarah S.

AU - Rodeberg, David

AU - Arndt, Carola A.S.

PY - 2014/11/8

Y1 - 2014/11/8

N2 - On the Fourth Intergroup Rhabdomyosarcoma study, older children experienced excessive neurotoxicity, whereas younger children had increased myelosuppression. The purpose of this study was to determine whether the same pattern of toxicity was seen on the successor study when use of growth factor was required and dosing of chemotherapy was different by performing a retrospective cohort analysis on patients treated on Children's Oncology Group protocol D9803. Toxicity data were analyzed by stratifying children into 4 age groups. The frequency of grade 3/4 neurotoxicity, myelosuppression, infection, and mucositis was predicted for each age group. The cumulative doses of vincristine and cyclophosphamide administered were measured as percent of protocol-prescribed dose. Adolescents (aged 15+) were more likely to experience neurotoxicity compared with younger patients (odds ratio, 3.6; P<0.0001). There was no difference in myelosuppression, infection, or mucositis. The mean percent protocol-prescribed doses administered for vincristine and cyclophosphamide did not differ much by age group. Adolescents experienced more neurotoxicity with vincristine compared with younger patients. No differences in other toxicities were observed between age groups. As adolescents received at least 85% of protocol-prescribed doses of vincristine, it is difficult to attribute the poorer survival in this age group to inadequate protocol-delivered therapy.

AB - On the Fourth Intergroup Rhabdomyosarcoma study, older children experienced excessive neurotoxicity, whereas younger children had increased myelosuppression. The purpose of this study was to determine whether the same pattern of toxicity was seen on the successor study when use of growth factor was required and dosing of chemotherapy was different by performing a retrospective cohort analysis on patients treated on Children's Oncology Group protocol D9803. Toxicity data were analyzed by stratifying children into 4 age groups. The frequency of grade 3/4 neurotoxicity, myelosuppression, infection, and mucositis was predicted for each age group. The cumulative doses of vincristine and cyclophosphamide administered were measured as percent of protocol-prescribed dose. Adolescents (aged 15+) were more likely to experience neurotoxicity compared with younger patients (odds ratio, 3.6; P<0.0001). There was no difference in myelosuppression, infection, or mucositis. The mean percent protocol-prescribed doses administered for vincristine and cyclophosphamide did not differ much by age group. Adolescents experienced more neurotoxicity with vincristine compared with younger patients. No differences in other toxicities were observed between age groups. As adolescents received at least 85% of protocol-prescribed doses of vincristine, it is difficult to attribute the poorer survival in this age group to inadequate protocol-delivered therapy.

KW - Age

KW - Chemotherapy

KW - Mucositis

KW - Neurotoxicity

KW - Neutropenia

KW - Rhabdomyosarcoma

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84918542917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918542917&partnerID=8YFLogxK

M3 - Article

C2 - 24936741

AN - SCOPUS:84918542917

VL - 36

SP - 599

EP - 604

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 8

ER -